EGFR+ Lung Cancer

Following treatment osimertinib, EGFR C797X mutations are now the leading mechanism of acquired resistance, outpacing MET amplification.

Amivantamab in combination with lazertinib and chemotherapy combination demonstrated encouraging responses in EGFR-mutant non–small cell lung cancer.

During a Targeted Oncology case-based roundtable event, Christine Bestvina, MD, discussed the outcomes of clinical trials of the EGFR exon 20-targeted agents amivantamab and mobocertinib with participants. This is the second of 2 articles based on this event.

Results from a phase 2 study show poziotinib demonstrates significant antitumor activity for patients with EGFR exon 20 positive non–small cell lung cancer.

During a live virtual event, Christine Bestvina, MD, discussed the use of amivantamab and mobocertinib, 2 new targeted therapies for patients with non–small cell lung cancer and an EGFR exon 20 insertion.

Andreas Saltos, MD, discusses the key takeaways of the phase 1/1b clinical trial exploring the use of binimetinib plus erlotinib in patients with non–small cell lung cancer harboring either KRAS or EGFR mutations.

Joshua K. Sabari, MD, discusses the significance of EGFR exon 20 insertion mutations in patients with non–small cell lung cancer.

Correlations between non–small cell lung cancer the metastasizes to the brain and enriched CDKN2A/B and EGFR alterations calls for further genomic exploration of this patient population.

In patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer that has progressed after mobocertinib treatment, remaining on mobocertinib may be warranted, according to news research.

Data from the phase 1/2a CLN-081-001 trial showed the clinical benefit of CLN-081 in patients with EGFR exon 20 insertion-positive non–small cell lung cancer.

Oritinib demonstrated almost complete disease control in previously treated patients with EGFR T790M–mutant, locally advanced or metastatic non–small cell lung cancer.

During a live virtual event, Anne S. Tsao, MD, discussed the choice of targeted therapy for a patient with non–small cell lung cancer with an EGFR exon 20 insertion.

Results of a phase 1 study of a fourth-generation EGFR tyrosine kinase inhibitor will be presented at the International Association for the Study of Lung Cancer 2022 World Conference.

Aparna Hegde, MD, discusses the decision to use osimertinib as soon as possible in patients with EGFR-positive non–small cell lung cancer.

Danny Nguyen, MD, discusses next steps for research of mobocertinib in patients with EGFR-positive non–small cell lung cancer.

During a live virtual event, Matthew A. Gubens, MD, MS, and participants discussed their reactions to the ADAURA trial of osimertinib for patients with EGFR-positive non–small cell lung cancer.

Ravi Salgia, MD, explains how treatment with a tyrosine kinase inhibitor in patients with non–small cell lung cancer can lead to disease transformation.

In a subgroup analysis of patients with non-small cell lung cancer who have EGFR sensitizing mutations, the regimen of atezolizumab plus bevacizumab plus carboplatin, and paclitaxel, had a stonger survival benefit compared to other therapies.

During a live virtual event, Matthew A. Gubens, MD, MS, discussed adjuvant chemotherapy using carboplatin or cisplatin in patients with EGFR-positive non–small cell lung cancer.

The addition of bevacizumab to erlotinib did not demonstrated improvement in overall survival in patients with EGFR-mutant non–small cell lung cancer treated in a phase 3 study.

During a Targeted Oncology case-based roundtable event, Afshin Dowlati, MD, and participants discussed the challenges of molecular testing and how to use test results to introduce targeted treatments for patients with non–small cell lung cancer.

DZD9008 for the treatment of patients with locally advanced or metastatic non–small cell lung cancer harboring with EGFR exon20 insertion mutations is an investigative treatment strategy in a clinical trial.

Megan May, PharmD, discusses fitting newer targeted therapies into the treatment paradigm for EGFR exon 20 insertion mutation-positive non–small cell lung cancer.

Danny Nguyen, MD, discusses an analysis of efficacy and adverse events of mobocertinib in patients with EGFR-positive non–small cell lung cancer that was presented at the European Society for Medical Oncology 2021 Congress.

Results from the phase 2 OCEAN trial show that osimertinib is effective in treating central nervous system metastases from non–small cell lung cancer in patients with certain mutations.

Telisotuzumab vedotin has shown interim efficacy in patients with advanced or metastatic EGFR wild-type non–small cell lung cancer and has now been granted breakthrough therapy designation from the FDA

Patritumab deruxtecan has been granted a breakthrough therapy designation by the FDA to accelerate its development for the treatment of patients with metastatic or locally advanced EGFR-mutated non-small cell lung cancer with disease progression on or after treatment with a third-generation tyrosine kinase inhibitor and platinum-based therapies.

In patients with EGFR-positive non–small cell lung cancer who develop a T790M mutation after disease progression, chemo-antiangiogenesis may prove beneficial.

Tegavivint is being tested in combination with osimertinib in an effort to prolong overall survival and deepen response in EGFR+ NSCLC.